Danaher said revenues for the quarter ended September 26, 2025 increased 4.5% year-over-year to $6.1 billion, net earnings were $908 million and diluted net earnings per common share were $1.27.

1. 01

   Danaher said revenues for the quarter ended September 26, 2025 increased 4.5% year-over-year to $6.1 billion, net earnings were $908 million and diluted net earnings per common share were $1.27.

2. 02

   The company said non-GAAP adjusted diluted net earnings per common share for Q3 were $1.89, compared with $1.71 in the comparable prior-year period, and non-GAAP core revenue increased 3.0% year-over-year. By segment, core sales for Q3 grew 6.5% in Biotechnology, declined 1.0% in Life Sciences and grew 3.5% in Diagnostics.

3. 03

   Danaher said operating cash flow for the 3-month period was $1,662 million, compared with $1,513 million in the comparable prior-year period, and non-GAAP free cash flow was $1,370 million, compared with $1,226 million in the comparable prior-year period. Cash used in financing activities for the same period was $2,781 million.

4. 04

   The company said it is maintaining its full-year 2025 non-GAAP adjusted diluted net earnings per common share guidance range of $7.70 to $7.80. It added that non-GAAP core revenue is expected to grow low-single digits year-over-year for the full year.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.